Diversion-p64 Post Market Clinical Follow-Up Study to Assess Safety and Effectiveness of the p64 Flow Modulation Device

CompletedOBSERVATIONAL
Enrollment

450

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

June 30, 2020

Study Completion Date

June 30, 2020

Conditions
Intracranial Aneurysm
Trial Locations (26)

1431

St. Ivan Rilski Hospital, Sofia

1642

Clínica La Sagrada Familia, Buenos Aires

3600

Ziekenhuis Oost-Limburg, Genk

20089

IRCCS Istituto Clinico Humanitas, Rozzano

28205

Klinikum Bremen-Mitte, Bremen

33000

Groupe Hospitalier Pellegrin, Bordeaux

34295

Hôpital Gui de Chauliac (CHU Montpellier), Montpellier

37044

Hôpital Bretonneau (CHRU de Tours), Tours

45657

Knappschaftskrankenhaus Recklinghausen, Recklinghausen

69500

Hôpital Pierre Wertheimer, Bron

70174

Klinikum Stuttgart Katharinenhospital, Stuttgart

86156

Klinikum Augsburg, Augsburg

93053

Universitätsklinikum Regensburg, Regensburg

94275

Hôpital Bicêtre, Le Kremlin-Bicêtre

Unknown

Hôpital Pitié Salpétrière, Paris

CHRU Hôpital Maison-Blanche, Reims

HELIOS Klinikum Erfurt, Erfurt

Ospedale Bellaria Carlo Alberto Pizzardi, Bologna

NSI Burdenko, Moscow, Moscow

Federal Almazov North-West Medical Research Centre, Saint Petersburg

86-300

Regionalny Szpital Specjalistyczny, Grudziądz

50-556

Uniwersytecki Szpital Kliniczny we Wroclawiu, Wroclaw

010718

Life Memorial Hospital, Bucharest

EH4 2XU

Western General Hospital, Edinburgh

LS1 3EX

Leeds Teaching Hospitals NHS TRUST, Leeds

SW17 0QT

St George's Hospital, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Phenox GmbH

INDUSTRY

NCT02600364 - Diversion-p64 Post Market Clinical Follow-Up Study to Assess Safety and Effectiveness of the p64 Flow Modulation Device | Biotech Hunter | Biotech Hunter